Abstract
Evaluation of bone marrow morphology by experienced hematologists is key in the diagnosis of myeloid neoplasms, especially to detect subtle signs of dysplasia in myelodysplastic neoplasms (MDS). The majority of recently introduced deep learning (DL) models in cytomorphology rely heavily on manually drafted cell-level labels, a time-consuming, laborious process that is prone to substantial inter-observer variability, thereby representing a substantial bottleneck in model development. Instead, we used robust image-level labels for end-to-end DL and trained several state-of-the-art computer vision models on bone marrow smears of 463 patients with MDS, 1301 patients with acute myeloid leukemia (AML), and 236 bone marrow donors. For the binary classifications of MDS vs. donors and MDS vs. AML, we obtained an area-under-the-receiver-operating-characteristic (ROCAUC) of 0.9708 and 0.9945, respectively, in our internal test sets. Results were confirmed in an external validation cohort of 50 MDS patients with corresponding ROCAUC of 0.9823 and 0.98552, respectively. Explainability via occlusion sensitivity mapping showed high network attention on cell nuclei not solely of dysplastic cells. We not only provide a highly accurate model to detect MDS from bone marrow smears, but also underline the capabilities of end-to-end learning to solve the bottleneck of time-consuming cell-level labeling.
Competing Interest Statement
J-NE, TS, SR, and JMM are co-owners of Cancilico.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All studies were approved by the Institutional Review Board of the Dresden University of Technology (EK 98032010 and EK 289112008).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Competing Interests: The authors declare no competing interests.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
List of Abbreviations
- AML
- acute myeloid leukemia
- BMS
- bone marrow smear(s)
- CNN
- convolutional neural net
- DL
- deep learning
- MDS
- myelodysplastic neoplasm(s)
